Kulhankova, Katarina http://orcid.org/0000-0001-7189-2323
Traore, Soumba
Cheng, Xue
Benk-Fortin, Hadrien
Hallée, Stéphanie
Harvey, Mario
Roberge, Joannie
Couture, Frédéric
Kohli, Sajeev
Gross, Thomas J. http://orcid.org/0000-0001-9617-6606
Meyerholz, David K. http://orcid.org/0000-0003-1552-3253
Rettig, Garrett R. http://orcid.org/0000-0003-4634-5787
Thommandru, Bernice
Kurgan, Gavin http://orcid.org/0000-0002-4047-1427
Wohlford-Lenane, Christine
Hartigan-O’Connor, Dennis J.
Yates, Bradley P.
Newby, Gregory A.
Liu, David R.
Tarantal, Alice F.
Guay, David http://orcid.org/0000-0003-0508-1703
McCray, Paul B. Jr. http://orcid.org/0000-0002-4067-577X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U24 HG010423)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (across all consortium initiatives52. Studies were also supported by U24 HG010423, P01, P01 HL152960)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 1 February 2023
Accepted: 23 November 2023
First Online: 5 December 2023
Competing interests
: P.B.M. is on the SAB and performs sponsored research for Spirovant Sciences, Inc. D.G. holds equity in Feldan Therapeutics. X.C., M.H. and D.G. are employees of Feldan Therapeutics. S.H., H.B.F. and J.R. were employees of Feldan Therapeutics. D.G. is co-inventor on patents and patent applications filed by Feldan Bio Inc. on the Shuttle peptide technology. D.R.L. is a consultant and equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver gene editing or epigenome modulating agents. D.R.L. and G.A.N. are co-inventors on patent applications filed by the Broad Institute on base editing and its applications. The remaining authors declare no competing interests.